AIX-EN-PROVENCE, France--(BUSINESS WIRE)--Regulatory News:
SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, PEA-PME eligible), the highly-innovative ultrasound company, today announces the appointment of Michèle Lesieur as President and CEO, thus replacing Bernard Doorenbos.
Michael Brock, Chairman of the Supervisory Board, says: “SuperSonic Imagine’s Supervisory Board is enthusiastic about Michèle Lesieur becoming the Company’s President and CEO. Her expertise, her leadership and her significant experience in international healthcare companies made her the best candidate to run SuperSonic Imagine, thus replacing Bernard Doorenbos, who was interim President and CEO. Indeed, we would like to thank Bernard for his contribution. Under Michèle’s experienced leadership, the Company will continue to implement its strategic plan, which consists in moving forward on its various markets by capitalizing on the highly-innovative nature of its Aixplorer® ultrasound platform, launching new innovative features and products and developing new fruitful partnerships. Along with our dedicated employees and a strong leadership team now headed by Michèle Lesieur, the Supervisory Board is confident that the scene is set for resuming a strong development track going forward.”
Michèle Lesieur held various positions within the Philips group at domestic and international level. Over the last five years, she was the President of Philips France and Head of Philips Healthcare in France. Before that, Michèle spent five years in charge of Sales & Marketing for the group’s medical imaging systems at international level, after having spent six years heading the Philips Medical Systems division in France. Michèle Lesieur has substantial expertise in the consumer electronics and telecoms sectors, having been in turn Marketing Director of Philips Business Electronics France and Managing Director of a Philips Business Electronics department responsible for the international sales policy and development strategy. With a Masters degree in Physics from Paris XI University and a postgraduate degree in Optical Transmission and Signal Processing from the Institut Supérieur d’Optique, Michèle began her career in laboratories with the aim of developing video communication optical transmission systems.
Michèle Lesieur concludes: “I am proud to have this opportunity to provide SuperSonic Imagine with my experience and dynamism by becoming the Company’s new CEO. The unwavering commitment, cohesion and talent of its teams have led it to now possess ultrasound technology and products whose highly-innovative aspect provides practitioners with an opportunity to better diagnose and treat liver and breast pathologies in patients. The Company has solid assets, and I firmly believe that we will be able to rapidly develop its established activity in France and abroad.”
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler, Angio PL.U.S – Planewave UltraSensitive™ Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.